Skip to content
The Kids Research Institute Australia logo
Donate

Search

Asymptomatic CMV infections in long-term renal transplant recipients are associated with the loss of FcRγ from LIR-1+ NK cells

CMV can be reactivated in symptom-free renal transplant recipients, affecting the phenotypic, and functional profiles of NK cells

Skin tumor immunity: Site does matter for antigen presentation by DCs

Timely mobilization of tumor antigen-bearing dendritic cells (DCs) from the periphery to the lymph nodes is critical for effective antitumor T-cell immunity

Cross-presentation of cutaneous melanoma antigen by migratory XCR1+CD103− and XCR1+CD103+ dendritic cells

This report provides new insight into the functional specialization within the broad network of dendritic cells that are responsible for skin immunosurveillance

T cells recognizing a 11mer influenza peptide complexed to H-2D b show promiscuity for peptide length

T-cell repertoire is selected according to self peptide-MHC (major histocompatibility complex) complexes in the thymus.

ErbB4 in the brain: Focus on high grade glioma

The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases (RTKs) consists of EGFR, ErbB2, ErbB3, and ErbB4. These receptors play key roles in cell proliferation, angiogenesis, cell migration, and in some cases, tumor promotion.

Experience of patients with lung cancer and with targeted therapy-related skin adverse drug reactions: A qualitative study

To explore the experience of non-small-cell lung cancer patients with targeted therapy-related skin adverse drug reactions.

Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action

Chemotherapy has historically been the mainstay of cancer treatment, but our understanding of what drives a successful therapeutic response remains limited.

Radiomics-A new age of presurgical assessment to improve outcomes in pediatric neuro-oncology

Citation: Valvi S, Hansford JR. Radiomics-A new age of presurgical assessment to improve outcomes in pediatric neuro-oncology. Neuro Oncol. 2022;24(6

Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations

Antibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4 (CTLA‐4) and the programmed cell death protein 1/ligand 1 (PD-1/PD-L1) are now a treatment option for multiple cancer types. However, as a monotherapy, objective responses only occur in a minority of patients. Chemotherapy is widely used in combination with immune checkpoint blockade (ICB). Although a variety of isolated immunostimulatory effects have been reported for several classes of chemotherapeutics, it is unclear which chemotherapeutics provide the most benefit when combined with ICB.